Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: Journal – The Jakarta Post – Jakarta Post
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emirates in a Phase 3 tria…
-
General17 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News23 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
General22 hours agoAustralia welcomes Gaza peace progress, hostage release
-
General15 hours agoHundreds attend justice march for Kaiden Morgan-Johnston in Morwell